SQSTM1 gene mutations may act as a potential threat by causing altered autophagy, resulting in pathogenic protein aggregation and the development of a variety of neurodegenerative diseases, including ALS and FTD.4 Furthermore,SQSTM1 mutations have been identified in patients with ALS and FTD.5 Serving as a signalling hub for neurodegenerative pathways, Sequestosome-1/p62 poses as a prospective therapeutic target in the treatment of neurodegenerative diseases.6 Mechanistic studies would be greatly facilitated with the availability of high-quality antibodies. This evidence concerns the gene SQSTM1 and neurodegenerative disease.